{"url_path":"/sec/okur/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1637715/0001193125-26-257423-index.html","accession_number":"0001193125-26-257423","cik":"0001637715","ticker":"OKUR","issuer_name":"OnKure Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1637715/0001193125-26-257423-index.html","primary_entity_key":"0001637715","primary_entity_name":"OnKure Therapeutics, Inc."},"word_count":225,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 3, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in the Proxy Statement.\n\nProposal No. 1: Election of Directors\n\nR. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D. and Edward T. Mathers were each elected to serve as a Class II director of the Company’s Board of Directors until the 2029 Annual Meeting of Stockholders and until their respective successors are elected and qualified, by the following votes:\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nNominee\n\nFor\n\nWithheld\n\nBroker Non-Votes\n\nR. Michael Carruthers\n\n19,776,757\n\n147,236\n\n5,466,123\n\nValerie M. Jansen, M.D., Ph.D.\n\n17,796,919\n\n2,127,074\n\n5,466,123\n\nEdward T. Mathers\n\n \n\n19,855,396\n\n \n\n68,597\n\n \n\n5,466,123\n\nProposal No. 2: Ratification of the Selection of Independent Registered Public Accounting Firm\n\nThe stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, by the following votes:\n\nFor\n\n \n\nAgainst\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n 25,329,425\n\n 60,370\n\n 321\n\n -\n\n \n\n \n\n \n\n \n\n \n\nProposal No. 3: Approval of the Amended and Restated 2024 Equity Incentive Plan\n\nThe stockholders approved the amendment and restatement of the Company’s 2024 Equity Incentive Plan, by the following votes:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n 16,431,575\n\n 3,490,523\n\n 1,895\n\n 5,466,123"}